Pharma seeks to offload old drugs

Share this article:

The industry merry-go-round of sales and swaps continues to spin. The Wall Street Journal reports that Sanofi, Merck and GlaxoSmithKline are independently exploring ways to offload their portfolios of older drugs. Insiders tell the Journal that Merck has been chatting up possible buyers of a series of drugs for about $15 billion, and that Sanofi is thinking of a joint venture to house some of its mature products.

GlaxoSmithKline, which recently participated in an asset swap with Novartis is also said to be contemplating divestment of older products.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.